238 related articles for article (PubMed ID: 27263854)
1. Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy.
Ueda-Sakane Y; Kanamoto N; Fushimi Y; Tanaka-Mizuno S; Yasuno S; Miura M; Sone M; Yasoda A; Okada T; Togashi K; Nakao K; Inagaki N
Endocr J; 2016 Aug; 63(8):703-14. PubMed ID: 27263854
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
[TBL] [Abstract][Full Text] [Related]
3. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association.
Marcocci C; Watt T; Altea MA; Rasmussen AK; Feldt-Rasmussen U; Orgiazzi J; Bartalena L;
Eur J Endocrinol; 2012 Feb; 166(2):247-53. PubMed ID: 22058081
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy.
Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B
Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves' ophthalmopathy: a prospective, randomized controlled trial.
He Y; Mu K; Liu R; Zhang J; Xiang N
Endocr J; 2017 Feb; 64(2):141-149. PubMed ID: 27853049
[TBL] [Abstract][Full Text] [Related]
7. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe?
Miśkiewicz P; Kryczka A; Ambroziak U; Rutkowska B; Główczyńska R; Opolski G; Kahaly G; Bednarczuk T
Endokrynol Pol; 2014; 65(5):402-13. PubMed ID: 25301492
[TBL] [Abstract][Full Text] [Related]
8. Intravenous Glucocorticoid Treatment for Korean Graves' Ophthalmopathy Patients.
Ahn HY; Lee JK
J Korean Med Sci; 2020 Jun; 35(23):e177. PubMed ID: 32537950
[TBL] [Abstract][Full Text] [Related]
9. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
[TBL] [Abstract][Full Text] [Related]
10. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.
Zang S; Ponto KA; Kahaly GJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):320-32. PubMed ID: 21239515
[TBL] [Abstract][Full Text] [Related]
11. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
[TBL] [Abstract][Full Text] [Related]
12. Smoking was associated with poor response to intravenous steroids therapy in Graves' ophthalmopathy.
Xing L; Ye L; Zhu W; Shen L; Huang F; Jiao Q; Zhou X; Wang S; Wang W; Ning G
Br J Ophthalmol; 2015 Dec; 99(12):1686-91. PubMed ID: 26061160
[TBL] [Abstract][Full Text] [Related]
13. Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy.
Sisti E; Coco B; Menconi F; Leo M; Rocchi R; Latrofa F; Profilo MA; Mazzi B; Vitti P; Marcocci C; Brunetto M; Marinò M
Thyroid; 2015 Jul; 25(7):846-50. PubMed ID: 26090805
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens.
Sánchez-Ortiga R; Moreno-Pérez O; González Sánchez V; Arias Mendoza N; Mauri Dot M; Alfayate Guerra R; López Macia A; Picó Alfonso A
Endocrinol Nutr; 2009 Mar; 56(3):118-22. PubMed ID: 19627724
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
Currò N; Covelli D; Vannucchi G; Campi I; Pirola G; Simonetta S; Dazzi D; Guastella C; Pignataro L; Beck-Peccoz P; Ratiglia R; Salvi M
Thyroid; 2014 May; 24(5):897-905. PubMed ID: 24417307
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of intravenous glucocorticoid treatment in Graves' ophtalmopathy.
Alhambra Expósito MR; Gálvez Moreno MÁ; Moreno Moreno P; Prior Sánchez I; Muñoz Jiménez C; Benito López P
Endocrinol Nutr; 2013 Jan; 60(1):10-4. PubMed ID: 23177093
[TBL] [Abstract][Full Text] [Related]
18. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.
Kahaly GJ; Pitz S; Hommel G; Dittmar M
J Clin Endocrinol Metab; 2005 Sep; 90(9):5234-40. PubMed ID: 15998777
[TBL] [Abstract][Full Text] [Related]
19. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.
Riedl M; Kolbe E; Kampmann E; Krämer I; Kahaly GJ
J Endocrinol Invest; 2015 Feb; 38(2):177-82. PubMed ID: 25576458
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
